KR20210005526A - Compositions and products containing phlorotannin for enhancing intestinal function - Google Patents
Compositions and products containing phlorotannin for enhancing intestinal function Download PDFInfo
- Publication number
- KR20210005526A KR20210005526A KR1020200081536A KR20200081536A KR20210005526A KR 20210005526 A KR20210005526 A KR 20210005526A KR 1020200081536 A KR1020200081536 A KR 1020200081536A KR 20200081536 A KR20200081536 A KR 20200081536A KR 20210005526 A KR20210005526 A KR 20210005526A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- composition
- ecklonia
- fluorotannin
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 130
- 230000003871 intestinal function Effects 0.000 title claims abstract description 78
- 229920001339 phlorotannin Polymers 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 title 1
- 230000000694 effects Effects 0.000 claims abstract description 17
- 201000006549 dyspepsia Diseases 0.000 claims abstract description 12
- 206010010774 Constipation Diseases 0.000 claims abstract description 4
- 208000024798 heartburn Diseases 0.000 claims abstract description 3
- 241001512723 Ecklonia Species 0.000 claims description 28
- 235000013305 food Nutrition 0.000 claims description 25
- 206010000060 Abdominal distension Diseases 0.000 claims description 20
- 235000013361 beverage Nutrition 0.000 claims description 20
- 230000006872 improvement Effects 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 14
- 208000024330 bloating Diseases 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- 208000024891 symptom Diseases 0.000 claims description 11
- 230000000968 intestinal effect Effects 0.000 claims description 10
- 241000230129 Eisenia <Phaeophyceae> Species 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 claims description 5
- CQSRUKJFZKVYCY-UHFFFAOYSA-N 5alpha-isofucostan-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 CQSRUKJFZKVYCY-UHFFFAOYSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229920000855 Fucoidan Polymers 0.000 claims description 5
- GBBBJSKVBYJMBG-QTWVXCTBSA-N Fucosterol Natural products CC=C(CC[C@@H](C)[C@@H]1CC[C@@H]2[C@H]3C=C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3CC[C@@]12C)C(C)C GBBBJSKVBYJMBG-QTWVXCTBSA-N 0.000 claims description 5
- OSELKOCHBMDKEJ-VRUYXKNBSA-N Isofucosterol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C OSELKOCHBMDKEJ-VRUYXKNBSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 239000000783 alginic acid Substances 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 229960001126 alginic acid Drugs 0.000 claims description 5
- 150000004781 alginic acids Chemical class 0.000 claims description 5
- OSELKOCHBMDKEJ-JUGJNGJRSA-N fucosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC\C(=C/C)C(C)C)[C@@]1(C)CC2 OSELKOCHBMDKEJ-JUGJNGJRSA-N 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 241001474374 Blennius Species 0.000 claims description 4
- 241000741680 Ecklonia arborea Species 0.000 claims description 4
- 241001512722 Ecklonia cava Species 0.000 claims description 4
- 229920001543 Laminarin Polymers 0.000 claims description 4
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 235000012054 meals Nutrition 0.000 claims description 4
- 241000195493 Cryptophyta Species 0.000 claims description 3
- 241000653613 Ecklonia radicosa Species 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 241000946389 Ecklonia kurome Species 0.000 claims description 2
- 241001392689 Ecklonia maxima Species 0.000 claims description 2
- 241000983748 Ecklonia radiata Species 0.000 claims description 2
- 241000439005 Ecklonia stolonifera Species 0.000 claims description 2
- 241000243681 Eisenia bicyclis Species 0.000 claims description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 2
- 230000000291 postprandial effect Effects 0.000 claims description 2
- 235000011837 pasties Nutrition 0.000 claims 1
- 241000199919 Phaeophyceae Species 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 2
- 206010051244 Dyschezia Diseases 0.000 abstract 1
- 230000003187 abdominal effect Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 54
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- 210000004347 intestinal mucosa Anatomy 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 239000004375 Dextrin Substances 0.000 description 7
- 229920001353 Dextrin Polymers 0.000 description 7
- 235000019425 dextrin Nutrition 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000013616 tea Nutrition 0.000 description 6
- 230000001079 digestive effect Effects 0.000 description 5
- 235000013373 food additive Nutrition 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000012263 liquid product Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000006694 eating habits Nutrition 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- AWFYPPSBLUWMFQ-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=C2 AWFYPPSBLUWMFQ-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229920002306 Glycocalyx Polymers 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 239000002038 ethyl acetate fraction Substances 0.000 description 2
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 description 2
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000004517 glycocalyx Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007413 intestinal health Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000007637 bowel dysfunction Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000020981 healthy eating habits Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/202—Algae extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 장기능 개선 효과를 갖는 플로로탄닌을 유효성분으로 포함하는 조성물 및 제품에 관한 것이다. 본 발명의 조성물 및 제품을 음료, 물, 차류, 식품 등에 첨가하여 섭취를 하면 장기능이 개선된다. 또한 본 발명의 조성물 및 제품은 천연성분을 주원료로 하여 안전하게 장기간 복용이 가능하다.The present invention relates to a composition and a product comprising as an active ingredient fluorotannin having an effect of improving intestinal function. When the composition and product of the present invention are added to beverages, water, teas, foods, etc. and ingested, intestinal function is improved. In addition, the composition and product of the present invention can be safely taken for a long time by using natural ingredients as the main ingredient.
최근 들어 스트레스, 불규칙한 식습관, 인스턴트 식품 섭취, 식품첨가물의 과다 섭취 등의 이유로 장건강이 악화되어 배변 및 소화에 장애를 경험하는 사람의 수가 늘고 있다. Recently, the number of people experiencing bowel and digestive disorders is increasing due to deterioration in intestinal health due to stress, irregular eating habits, consumption of instant food, and excessive intake of food additives.
많은 사람들이 스트레스를 경감시키기 위해 여러가지 활동을 하고 치료를 받기도 하지만 사회생활에 필연적으로 따라오는 스트레스 원인을 모두 제거하기는 힘들다. 한편 스트레스로 인한 소화 장애 및 배변 장애를 겪는 경우 효과적인 치료약도 없어 건강에 약영향을 주고 일상 생활을 불편하게 만든다. 또한 소화장애 또는 배변장애에 따른 더부룩한 느낌은 일상생활에 불편을 주고 항상 불안한 심리상태를 유발하여 만성질환을 유발할 가능성도 있다. Many people do various activities and receive treatment to relieve stress, but it is difficult to eliminate all the causes of stress that inevitably follow in social life. On the other hand, when suffering from digestive disorders and bowel movements due to stress, there are no effective treatments, which affects health and makes daily life uncomfortable. In addition, the feeling of bloating caused by digestive disorders or defecation disorders may cause discomfort in daily life and always lead to an uneasy psychological state, leading to chronic diseases.
또한 현대에는 많은 사람들이 바쁜 일상생활로 인해 균형이 잡힌 식생활을 못하고 식품첨가물이 많이 함유된 인스턴스 식품을 섭취하는 경우가 늘고 있는데, 이 경우 장기능 저하가 발생하고 신체건강 전반에 악영향을 주고 있다. In addition, in modern times, many people cannot eat a balanced diet due to their busy daily life and consume instant foods containing a lot of food additives. In this case, intestinal function declines and the overall physical health is adversely affected.
건강을 유지하기 위해 건강한 식습관 및 스트레스를 덜 받는 것이 중요하지만 바쁜 현대인에게는 어려운 과제이기도 하다. 최근 들어 장기능 개선을 위한 프로바이오틱스류 및 식이섬유를 이용한 제품이 많이 출시되고 있으나 건강기능식품, 약품처럼 주기적으로 정량을 섭취해야 하고 접근이 어렵다는 단점이 있다.Healthy eating habits and less stress are important to maintain health, but it is also a difficult task for busy modern people. Recently, a lot of products using probiotics and dietary fiber for improving intestinal function have been released, but there is a disadvantage in that it is difficult to access and require periodic intake of doses like health functional foods and drugs.
장기능 개선에 대한 선행기술을 살펴보면 대한민국 등록특허 제10-0486630호에서 차전차피 분말을 첨가하여 기능성 식이섬유 보충을 통한 만복감 증가, 배변량 증가를 유도해 장기능을 개선하는 보충용 식품을 제공하고 있다. 대한민국 등록특허 제10-1979698호에서는 죽순 효소분획물 및 발효물을 유효성분으로 하는 장기능 저하예방, 개선용 조성물을 제공한다.Looking at the prior art for improving bowel function, Korean Patent Registration No. 10-0486630 provides supplementary food that improves bowel function by inducing increased feeling of fullness and increased bowel volume through supplementation of functional dietary fiber by adding chajeon chapi powder. . Republic of Korea Patent Registration No. 10-1979698 provides a composition for preventing and improving bowel function decline, using an enzyme fraction of bamboo shoots and a fermented product as active ingredients.
그러나 상기 특허의 만복감 증가 또는 배변량 증가는 과할 경우 불쾌감을 주고 일상생활에서 불편함을 초래할 수 있다.However, the increase in the feeling of fullness or the increase in the amount of bowel movement of the patent may cause discomfort and discomfort in daily life if excessive.
본 발명에서는 선행기술과 달리 만복감과 배변량의 증가 없이 장기능 개선의 효과를 갖는 기능성 조성물 및 이를 포함하는 제품을 제공하고자 한다.In the present invention, unlike the prior art, it is intended to provide a functional composition having an effect of improving bowel function and a product including the same without increasing a feeling of fullness and bowel movement.
본 발명은 장의 활동 및 기능을 개선하는 효과를 갖는 조성물 및 제품을 제공함으로써, 스트레스 및 불규칙한 식습관으로 인해 장기능 장애를 겪는 사람들의 불편을 경감시켜 건강을 개선하고자 한다. 또한 분말형, 액상 등의 여러 형태의 제품을 제공하여 사용자가 편리하게 접근 및 적용할 수 있도록 하고자 한다.The present invention aims to improve health by reducing discomfort of people suffering from intestinal dysfunction due to stress and irregular eating habits by providing compositions and products having an effect of improving intestinal activity and function. In addition, by providing various types of products such as powder and liquid, users can conveniently access and apply them.
상기의 목적을 달성하기 위해 본 발명은 플로로탄닌을 유효성분으로 포함하는 장기능 개선용 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for improving intestinal function comprising fluorotannin as an active ingredient.
또한 본 발명은 상기 조성물을 포함하는 제품을 제공한다.In addition, the present invention provides a product comprising the composition.
본 발명의 플로로탄닌을 유효성분으로 포함하는 장기능 개선용 조성물 및 제품은 갈조류 유래의 안전한 천연화합물을 포함하고 방부제 등의 유해 화학물질, 식품첨가물 등을 포함하지 않아 안전하게 사용이 가능하고 부작용의 염려가 없다. 본 발명의 플로로탄닌을 유효성분으로 포함하는 장기능 개선용 조성물 및 제품은 일상적으로 섭취하는 음료, 식품 등에 간단히 첨가하여 간편하게 섭취할 수 있는 효과가 있다. 또한 본 발명의 조성물 및 제품은 장기능 개선에 도움을 주며 일상생활 중 불편함을 해소하여 삶의 질을 개선하는 효과가 있다.The composition and product for improving bowel function containing fluorotannin as an active ingredient of the present invention contain safe natural compounds derived from brown algae and do not contain harmful chemicals such as preservatives, food additives, etc., so they can be safely used and have side effects. No worries Compositions and products for improving intestinal function containing fluorotannin of the present invention as an active ingredient have an effect that can be easily ingested by simply adding them to beverages and foods that are consumed on a daily basis. In addition, the compositions and products of the present invention are effective in improving the intestinal function and improving the quality of life by relieving discomfort in daily life.
도 1은 세포차원에서의 장점막의 구조를 나타낸 도이다.
도 2는 실시예 2의 제품예 3을 나타낸 도이다.
도 3은 실시예 3의 제품예 8을 나타낸 도이다.1 is a diagram showing the structure of the intestinal mucosa at the cell level.
2 is a diagram showing Product Example 3 of Example 2.
3 is a diagram showing Product Example 8 of Example 3. FIG.
이하 본 발명에 대해 상세히 설명한다.Hereinafter, the present invention will be described in detail.
사회가 고도화되면서 식품첨가물이 많이 포함되어 있는 인스턴트 식품의 섭취가 늘어나고 바쁜 생활로 인해 불규칙적인 식사와 과도한 스트레스로 장기능 저하의 문제를 경험하는 사람이 늘고 있다. 장기능의 저하는 소화불량, 복부팽만감, 배변장애 등의 형태로 나타나며, 영양 불균형 및 면역력 이상을 초래하여, 건강을 악화시키며 삶의 질을 저하시킨다. As society is advanced, consumption of instant foods containing a lot of food additives increases, and more and more people experience problems of intestinal function decline due to irregular meals and excessive stress due to busy life. Deterioration in intestinal function appears in the form of indigestion, bloating, and bowel disorders, and causes nutritional imbalance and immunity, deteriorating health and quality of life.
장 점막은 인체의 내부와 외부 환경 (음식물, 미생물 등)의 경계로서, 섭취된 유해물질 및 장내세균들에 의해 장점막이 손상되면, 유해 성분이 체내로 침투하여 염증 반응이 일어나게 되어 장의 건강을 훼손시키고 나아가 각종 질병을 유발한다.The intestinal mucosa is the boundary between the human body's internal and external environments (food, microorganisms, etc.).When the intestinal mucosa is damaged by ingested harmful substances and intestinal bacteria, harmful components penetrate into the body and inflammatory reactions occur, thereby damaging the intestinal health. In addition, it causes various diseases.
장 점막을 세포학적 차원에서 관찰하면, 도 1과 같이, 외부 물질과 만나는 최외각은 글리코칼릭스(glycocalyx)로 뒤덮인 미세돌기 (microvilli) 로 되어 있다. 글리코칼릭스(Glycocalyx)는 세포막에 존재하는 당단백질 및 당지질에 부착된 올리고당(oligosaccharide)으로써, 물과 함께 촘촘한 하이드로네트워크(hydronetwork)을 형성하여 분자수준의 영양분은 흡수될 수 있지만, 상대적으로 거대한 크기의 미생물은 장내로 침투할 수 없게 점액 형태로 방어선을 형성하고 있다. 그러나, 각종 식품첨가제, 알코올, 상한기름(과산화지질) 등의 화학 작용 및 부적절한 식습관 (섬유질 비섭취 등)으로 인한 유해세균 득세에 의해 이 하이드로네트워크(hydronetwork)이 손상되어 뚫리게 될 수 있다.When the intestinal mucosa is observed from the cytological level, as shown in FIG. 1, the outermost shell that meets the foreign material is made of microvilli covered with glycocalyx. Glycocalyx is an oligosaccharide attached to glycoproteins and glycolipids present in the cell membrane.It forms a dense hydronetwork with water, so that nutrients at the molecular level can be absorbed, but relatively large in size. Microorganisms in the intestine form a defense line in the form of mucus so that they cannot penetrate the intestine. However, the hydronetwork may be damaged and punctured by the influx of harmful bacteria due to chemical reactions such as various food additives, alcohol, and high-limit oil (peroxylipid) and inappropriate eating habits (non-intake of fiber, etc.).
본 발명자들은 이러한 하이드로네크워크의 강화 또는 손상된 하이드로네트워크의 회복에 대하여 연구하던 중 플로로탄닌이 이러한 하이드로네크워크의 강화 또는 손상된 하이드로네트워크의 회복에 도움을 줄 수 있다는 것을 발견하고 지속적인 연구를 수행하여 본 발명을 완성하였다.The inventors of the present invention discovered that fluorotannin can help strengthen the hydronetwork or restore the damaged hydronetwork while studying the reinforcement of such a hydronetwork or the recovery of the damaged hydronetwork, and the present invention Was completed.
본 발명자들은 식용 갈조류에서 추출하고 정제한 플로로탄닌 화합물이 포함된 음료수를 섭취한 경우, 많은 사람들에 있어서 식사 후 더부룩함 및 복부팽만감과 같은 소화 불량 증상, 장내 가스가 차는 증상, 변비 증상이 완화되는 경우가 많음에 착안하여 다양한 사례 및 사용 방법에 대한 연구를 수행한 끝에 플로로탄닌의 섭취가 하이드로네크워크의 강화 또는 손상된 하이드로네트워크의 회복에 도움을 주어 악화된 장기능을 신속하게 회복시킴을 확인함으로써 본 발명을 완성하였다. When the present inventors ingested a drink containing a fluorotannin compound extracted and purified from edible brown algae, indigestion symptoms such as bloating and bloating after a meal, symptoms of intestinal gas filling, and constipation symptoms in many people are alleviated. After conducting research on various cases and methods of use, conceiving that there are many cases, it was confirmed that the intake of fluorotannin helped strengthen the hydronetwork or restore the damaged hydronetwork, thereby quickly recovering the deteriorated intestinal function. By doing this, the present invention was completed.
이에 본 발명은 플로로탄닌 화합물을 유효성분으로 포함하는 장기능 개선용 조성물을 제공한다. Accordingly, the present invention provides a composition for improving intestinal function comprising a fluorotannin compound as an active ingredient.
또한 본 발명은 상기 플로로탄닌을 유효성분으로 포함하는 조성물을 이용하여, 다양한 식품 및 음료에 손쉽게 첨가하여 사용이 가능한 장기능 개선용 제품을 제공한다. In addition, the present invention provides a product for improving intestinal function that can be easily added to various foods and beverages and used by using the composition containing the fluorotannin as an active ingredient.
갈조류에서 발견되는 플로로탄닌은 식용이 가능할 정도로 생체 친화적이며, 분자내에 10개 내외의 수산화기를 지니고 있어서 물분자 및 다양한 생체 고분자들과 수소결합을 통해 하이드로네트워크(hydronetwork)을 효과적으로 형성할 수 있다. 이러한 플로로탄닌 성분이 적정 농도로 장에 공급됨으로써 손상된 장점막의 하이드로네트워크의 복구를 촉진할 수 있다. 즉, 손상된 장 점막에 존재하는 올리고당과 하이드로네트워크(hydronetwork) 형성을 통하여 장점막의 손상의 복구를 촉진함으로써 장 점막이 회복될 때가지 미생물이나 미생물 유래의 염증 발현 물질의 체내 진입을 막아줄 수 있다. 또한 장 점막 하이드로네트워크에 플로로탄닌이 포진하게 됨으로써, 플로로탄닌의 항산화력, 항균력이 장 점막의 방어력을 한층 강화시켜 장내 유해 물질에 의해 발생된 활성산소 및 유해세균으로부터 장 본연의 기능을 지켜내는데 도움을 줄 수 있다.Phlotannin found in brown algae is bio-friendly enough to be edible, and has about 10 hydroxyl groups in the molecule, so it can effectively form a hydronetwork through hydrogen bonding with water molecules and various biopolymers. By supplying such a fluorotannin component to the intestine at an appropriate concentration, the repair of the hydronetwork of the damaged intestinal membrane can be promoted. That is, it is possible to prevent the intestinal mucosa from entering the body until the intestinal mucosa is restored by promoting the repair of damage to the intestinal mucosa through the formation of oligosaccharides and hydronetworks present in the damaged intestinal mucosa. In addition, as the intestinal mucosa hydronetwork is encapsulated with fluorotannin, the antioxidant and antibacterial properties of fluorotannin further strengthen the defense power of the intestinal mucosa to protect the intestinal function from free radicals and harmful bacteria generated by harmful substances in the intestine. You can help me.
상기 장기능 개선용 조성물은 플로로탄닌 화합물을 20 ~ 100 중량% 포함할 수 있다.The composition for improving bowel function may contain 20 to 100% by weight of a fluorotannin compound.
상기 장기능 개선용 조성물은 천연유래 성분으로, 통상적인 모든 방법에 의해 얻을 수 있다. 즉, 시판되는 시약을 사용하여 합성할 수도 있으며 천연물, 특히 해조류로부터 추출 및 분리하여 얻을 수도 있다.The composition for improving bowel function is a naturally derived component, and can be obtained by all conventional methods. That is, it can also be synthesized using commercially available reagents, and can also be obtained by extraction and separation from natural products, especially seaweed.
상기 장기능 개선용 조성물은 해조류 추출물일 수 있다. 상기 장기능 개선용 조성물은 해조류의 주정 추출물일 수 있다.The composition for improving intestinal function may be an algae extract. The composition for improving intestinal function may be an alcohol extract of seaweed.
상기 플로로탄닌을 유효성분으로 하는 장기능 개선용 조성물은 해조류, 특히 갈조류에서 추출할 수 있으며 구체적으로 대황(Eisenia bicyclis), 아이세니아 아르보레아(Eisenia arborea), 아이세니아 데스마레스티오데스(Eisenia desmarestioides), 아이세니아 갈라파제니스(Eisenia galapagensis), 아이세니아 매소니(Eisenia masonii), 검둥감태(Ecklonia kurome), 감태(Ecklonia cava), 곰피(Ecklonia stolonifera), 바다대나무(Ecklonia maxima), 에클로니아 라디아타(Ecklonia radiata), 에클로니아 바이시클리스(Ecklonia bicyclis), 에클로니아 바이런시네이트(Ecklonia biruncinate), 에클로니아 부시날리스(Ecklonia buccinalis), 에클로니아 카에파에스팁스(Ecklonia caepaestipes), 에클로니아 엑사스퍼타(Ecklonia exasperta), 에클로니아 파스티기아타(Ecklonia fastigiata), 에클로니아 브레빕스(Ecklonia brevipes), 에클로니아 아라보레아(Ecklonia arborea), 에클로니아 라티폴리아(Ecklonia latifolia), 에클로니아 무라티(Ecklonia muratii), 에클로니아 라디코사(Ecklonia radicosa), 에클로니아 리타디아나(Ecklonia richardiana) 및 에클로니아 라이티(Ecklonia wrightii)로 이루어진 그룹으로부터 선택된 1종 이상의 해조류로부터 추출된다.The composition for improving bowel function using fluorotannin as an active ingredient can be extracted from seaweed, especially brown algae, and specifically, Rhubarb (Eisenia bicyclis), Eisenia arborea, and Isenia desmarethiodes ( Eisenia desmarestioides), Eisenia galapagensis, Eisenia masonii, Ecklonia kurome, Ecklonia cava, Ecklonia stolonifera, Ecklonia maxima , Ecklonia radiata, Ecklonia bicyclis, Ecklonia biruncinate, Ecklonia buccinalis, Ecklonia caepaestipes , Ecklonia exasperta, Ecklonia fastigiata, Ecklonia brevipes, Ecklonia arborea, Ecklonia latifolia, Ecklonia muratii (Ecklonia muratii), Ecklonia radicosa (Ecklonia radicosa), Ecklonia richardiana (Ecklonia richardiana) and Ecklonia wrightii (Ecklonia wrightii) is extracted from at least one selected from the group consisting of algae.
본 발명의 조성물은 플로로탄닌 외에 탄수화물 성분으로서 만니톨, 알긴산, 푸코이단, 라미나란 및 지질 성분으로서 푸코스테롤, 푸코잔틴 등으로 구성되는 성분을 추가적으로 0-80중량% 함유할 수 있다.In addition to fluorotannin, the composition of the present invention may additionally contain 0-80% by weight of components consisting of mannitol, alginic acid, fucoidan, laminaran as a carbohydrate component, and fucosterol, fucoxanthine as a lipid component.
본 발명의 장기능 개선용 조성물은 바람직하게는 엑콜계 플로로탄닌을 포함할 수 있다.The composition for improving intestinal function of the present invention may preferably include an ecchol-based fluorotannin.
본 발명의 장기능 개선용 조성물은 바람직하게는 하기 화학식 1 ~ 화학식 12로 표시되는 화합물 중 선택되는 1종 이상의 플로로탄닌을 포함하는 경우 장 점막의 하이드로네트워크 강화 또는 손상의 회복에 도움을 줄 수 있다.When the composition for improving intestinal function of the present invention preferably contains at least one fluorotannin selected from compounds represented by the following Chemical Formulas 1 to 12, it can help strengthen the hydronetwork of the intestinal mucosa or recover damage. have.
[화학식 1][Formula 1]
[화학식 2][Formula 2]
[화학식 3][Formula 3]
[화학식 4][Formula 4]
[화학식 5][Formula 5]
[화학식 6][Formula 6]
[화학식 7][Formula 7]
[화학식 8][Formula 8]
[화학식 9][Formula 9]
[화학식 10][Formula 10]
[화학식 11][Formula 11]
[화학식 12][Formula 12]
본 발명의 장기능 개선용 조성물은 유효성분으로 상기 화학식 2, 화학식 4, 화학식 5, 화학식 6, 화학식 8 및 화학식 10으로 이루어진 그룹에서 선택되는 1종 이상의 플로로탄닌을 포함할 수 있다. 상기 플로로탄닌의 극성은 특히 장과 잘 맞을 수 있다.The composition for improving bowel function of the present invention may include at least one fluorotannin selected from the group consisting of Formula 2, Formula 4, Formula 5, Formula 6, Formula 8, and Formula 10 as an active ingredient. The polarity of the fluorotannin may be particularly well suited to the gut.
본 발명의 장기능 개선용 조성물은 유효성분으로 상기 화학식 2, 화학식 4, 화학식 5, 화학식 6, 화학식 8 및 화학식 10으로 이루어진 그룹에서 선택되는 2종 이상의 플로로탄닌을 포함할 수 있다.The composition for improving bowel function of the present invention may include two or more types of fluorotannins selected from the group consisting of Formula 2, Formula 4, Formula 5, Formula 6, Formula 8, and Formula 10 as an active ingredient.
본 발명의 장기능 개선용 조성물은 유효성분으로 상기 화학식 5, 화학식 6, 화학식 8 및 화학식 10으로 이루어진 그룹에서 선택되는 2종 이상의 플로로탄닌을 포함할 수 있다.The composition for improving bowel function of the present invention may include two or more types of fluorotannins selected from the group consisting of Chemical Formula 5, Chemical Formula 6, Chemical Formula 8, and Chemical Formula 10 as an active ingredient.
본 발명의 장기능 개선용 조성물은 유효성분으로 상기 화학식 5, 화학식 6, 화학식 8 및 화학식 10의 플로로탄닌을 포함할 수 있다.The composition for improving intestinal function of the present invention may include fluorotannin of Formula 5, Formula 6, Formula 8, and Formula 10 as an active ingredient.
본 발명의 장기능 개선용 조성물은 전체중량에 대하여 바람직하게는 화학식 2의 플로로탄닌 1 내지 60중량%, 화학식 4의 플로로탄닌 0.3 내지 34중량%, 화학식 5의 플로로탄닌 0.1 내지 24중량%, 화학식 6의 플로로탄닌 1 내지 24중량%, 화학식 8의 플로로탄닌 1 내지 26중량% 및 화학식 10의 플로로탄닌 1 내지 18중량%로 이루어진 그룹에서 선택되는 1종 이상을 포함할 수 있다.The composition for improving bowel function of the present invention is preferably 1 to 60% by weight of fluorotannin of formula 2, 0.3 to 34% by weight of fluorotannin of formula 4, 0.1 to 24% by weight of fluorotannin of formula 5 based on the total weight %, 1 to 24% by weight of fluorotannin of Formula 6, 1 to 26% by weight of fluorotannin of Formula 8, and 1 to 18% by weight of fluorotannin of Formula 10 may contain at least one selected from the group consisting of have.
본발명의 장기능 개선용 조성물은 전체 중량에 대하여 화학식 1의 플로로탄닌 0.1 ~ 3중량%, 화학식 2의 플로로탄닌 5 ~ 63중량%, 화학식 3의 플로로탄닌 1 ~ 3중량%, 화학식 4의 플로로탄닌 0.5 ~ 34중량%, 화학식 5의 플로로탄닌 0.1 ~ 50중량%, 화학식 6의 플로로탄닌 0.5 ~ 24중량%, 화학식 7의 플로로탄닌 0.1 ~ 1중량%, 화학식 8의 플로로탄닌 0.1 ~ 46중량%, 화학식 9의 플로로탄닌 0.1 ~ 2중량%, 화학식 10의 플로로탄닌 0.1 ~ 18중량%, 화학식 11의 플로로탄닌 0.1 ~ 3중량% 및 화학식 12의 플로로탄닌 0.1 ~ 4중량%를 포함할 수 있다.The composition for improving bowel function of the present invention comprises 0.1 to 3% by weight of fluorotannin of formula 1, 5 to 63% by weight of fluorotannin of formula 2, 1 to 3% by weight of fluorotannin of formula 3, and formula 0.5 to 34% by weight of fluorotannin of formula 4, 0.1 to 50% by weight of fluorotannin of formula 5, 0.5 to 24% by weight of fluorotannin of formula 6, 0.1 to 1% by weight of fluorotannin of formula 7 0.1 to 46% by weight of fluorotannin, 0.1 to 2% by weight of fluorotannin of formula 9, 0.1 to 18% by weight of fluorotannin of formula 10, 0.1 to 3% by weight of fluorotannin of formula 11 and fluoro of formula 12 It may contain 0.1 to 4% by weight of tannin.
본 발명의 장기능 개선용 조성물은 플로로탄닌 20~100중량%, 만니톨 0 내지 30 중량%, 알긴산 0 내지 25 중량%, 푸코이단 0 내지 25 중량%, 푸코스테롤 0 내지 10 중량%, 푸코잔틴 0 내지 10 중량%, 라미나란 0 내지 10 중량%을 포함할 수 있다.The composition for improving bowel function of the present invention is 20 to 100% by weight of fluorotannin, 0 to 30% by weight of mannitol, 0 to 25% by weight of alginic acid, 0 to 25% by weight of fucoidan, 0 to 10% by weight of fucosterol, 0 to fucoxanthine To 10% by weight, lamina may include 0 to 10% by weight.
본 발명의 장기능 개선용 조성물은 플로로탄닌 20 내지100중량%미만, 만니톨 0 초과 내지 30 중량%, 알긴산 0 초과 내지 25 중량%, 푸코이단 0 초과 내지 25 중량%, 푸코스테롤 0 초과 내지 10 중량%, 푸코잔틴 0 초과 내지 10 중량%, 라미나란 0 초과 내지 10 중량%을 포함할 수 있다.The composition for improving intestinal function of the present invention includes 20 to less than 100% by weight of fluorotannin, more than 0 to 30% by weight of mannitol, more than 0 to 25% by weight of alginic acid, more than 0 to 25% by weight of fucoidan, and more than 0 to 25% by weight of fucosterol. %, more than 0 to 10% by weight of fucoxanthin, and more than 0 to 10% by weight of laminaran.
본 발병의 장기능 개선용 조성물은 소화기능 및 배변 기능 개선에 효과적이다. 보다 구체적으로 속쓰림, 식후 더부룩한 증상, 위산 역류현상, 복부 팽만감, 장내 가스가 차는 증상의 개선에 효과적이며, 배변 활동이 원활하고 규칙적으로 되고, 배변이 쉬워지며 변비증상이 개선 된다. 또한, 방귀가 줄어들며, 변의 악취가 줄어 들고, 변의 질감이 부드러워진다. The composition for improving bowel function of the present disease is effective in improving digestive function and bowel function. More specifically, it is effective in improving heartburn, postprandial bloating symptoms, gastric acid reflux phenomenon, abdominal bloating, and intestinal gas filling symptoms, smooth and regular bowel movements, easier bowel movements, and improved constipation symptoms. In addition, there are fewer farts, less odor in the stool, and softer stool texture.
본 발병의 장기능 개선용 조성물은 공복시나 식음료와 함께 및 식후에 섭취할 수 있으나, 공복시 나 식음료와 함께 섭취함으로써 더욱 효과적이다.The composition for improving bowel function of the present disease can be consumed on an empty stomach, with food and beverage, and after meals, but is more effective by ingesting it on an empty stomach or with food and beverage.
장기능 개선을 위한 본 발명의 장기능 개선용 조성물의 일일 섭취량은 0.01 ~ 1000 mg, 바람직하게는 0.5 ~ 100 mg이다.The daily intake of the composition for improving bowel function of the present invention for improving bowel function is 0.01 to 1000 mg, preferably 0.5 to 100 mg.
본 발명의 장기능 개선용 조성물은 식품, 음료, 차류, 물 등에 첨가하여 섭취하기 용이하게 하기 위하여 분말 또는 액상의 형태일 수 있다.The composition for improving bowel function of the present invention may be in the form of a powder or liquid in order to facilitate intake by adding to food, beverages, teas, water, and the like.
본 발명은 상기 플로로탄닌을 포함하는 조성물을 포함하는 식품, 차류, 물 및 음료 첨가용 제품을 제공한다.The present invention provides a product for adding food, tea, water and beverages comprising a composition containing the fluorotannin.
본 발명의 식품 및 음료 첨가용 제품은 분말 또는 액상형태로 제품화 될 수 있다.The product for food and beverage addition of the present invention may be commercialized in a powder or liquid form.
본 발명의 식품 및 음료 첨가용 제품은 플로로탄닌을 포함하는 장기능 개선용 조성물과 함께 보조성분으로 증점제, 보존제, 물 등을 포함할 수 있다. 본 발명의 제품은 플로로탄닌을 포함하는 장기능 개선용 조성물과 함께 덱스트린, 펙틴, 아미노산, 구연산, 무기염류, 비타민, 물 등을 포함할 수 있다. The product for adding food and beverages of the present invention may contain a thickener, a preservative, water, etc. as auxiliary ingredients along with a composition for improving bowel function including fluorotannin. The product of the present invention may contain dextrin, pectin, amino acid, citric acid, inorganic salts, vitamins, water, and the like, along with a composition for improving intestinal function containing fluorotannin.
상기 식품, 차류, 물 및 음료 첨가용 제품은 플로로탄닌 포함 장기능 개선용 조성물을 제품 총 중량대비 바람직하게는 0.001 ~ 50중량% 더욱 바람직하게는 0.1~10중량% 포함할 수 있으나, 배합량이 상기의 범위에 한정되는 것은 아니다. 본 발명의 식품 및 음료 첨가용 제품이 장기능 개선용 조성물을 상기 함량으로 포함할 경우 장기능 개선의 효과를 줄 수 있고 건강관리에 도움을 줄 수 있다.The product for the addition of food, tea, water and beverages may contain preferably 0.001 to 50% by weight and more preferably 0.1 to 10% by weight of a composition for improving bowel function including fluorotannin, based on the total weight of the product, It is not limited to the above range. When the food and beverage addition product of the present invention contains the composition for improving intestinal function in the above content, it can give an effect of improving intestinal function and help in health management.
상기 장기능 개선용 분말형 제품은 바람직하게는 본 발명의 장기능 개선용 조성물 1 ~ 50중량%와 덱스트린 40 ~ 99중량%, 칼슘 0 ~ 15중량%, 철분 0 ~ 0.8중량%, 비타민 B12 0 ~ 0.01중량%, 비타민 E 0 ~ 0.3중량% 및 구리 0 ~ 0.1중량%를 포함할 수 있다. 이 경우 장기능을 개선하고 건강이 증진되는 효과가 있다.The powdered product for improving bowel function is preferably 1 to 50% by weight of the composition for improving bowel function of the present invention, 40 to 99% by weight of dextrin, 0 to 15% by weight of calcium, 0 to 0.8% by weight of iron, and vitamin B12 0 It may contain ~ 0.01% by weight, 0 ~ 0.3% by weight of vitamin E and 0 ~ 0.1% by weight of copper. In this case, there is an effect of improving intestinal function and promoting health.
상기 장기능 개선용 액상형 제품은 바람직하게는 본 발명의 장기능 개선용 조성물 0.01 ~ 30중량%와 물 70 ~ 99.99중량%, 덱스트린 0 ~ 50중량%, 칼슘 0 ~ 15중량%, 철분 0 ~ 0.8중량%, 비타민 B12 0 ~ 0.01중량%, 비타민 E 0 ~ 0.3중량% 및 구리 0 ~ 0.1중량%를 포함할 수 있다. 이 경우 장기능을 개선하고 건강이 증진되는 효과가 있다.The liquid product for improving bowel function is preferably 0.01 to 30% by weight of the composition for improving bowel function of the present invention, 70 to 99.99% by weight of water, 0 to 50% by weight of dextrin, 0 to 15% by weight of calcium, 0 to 0.8 of iron. It may contain 0 to 0.01% by weight of vitamin B12, 0 to 0.3% by weight of vitamin E, and 0 to 0.1% by weight of copper. In this case, there is an effect of improving intestinal function and promoting health.
본 발명의 식품 및 음료 첨가용 제품에 포함되는 플로로탄닌의 1일 사용량은 0.01 ~ 1000 mg, 바람직하게는 0.5 ~ 100 mg 정도이나 사용량이 상기의 범위에 한정되는 것은 아니다.The daily amount of fluorotannin contained in the product for food and beverage addition of the present invention is 0.01 to 1000 mg, preferably about 0.5 to 100 mg, but the amount used is not limited to the above range.
이하에서 실시예 및 실험예를 통하여 본 발명을 보다 상세히 설명한다. 그러나 하기의 실시예 및 실험예는 본 발명을 더욱 구체적으로 설명하기 위한 것으로서, 본 발명의 범위가 하기의 실시예 및 실험예에 의하여 한정되는 것은 아니다. 하기의 실시예 및 실험예는 본 발명의 범위 내에서 당업자에 의해 적절히 수정, 변경될 수 있다.Hereinafter, the present invention will be described in more detail through examples and experimental examples. However, the following examples and experimental examples are intended to more specifically illustrate the present invention, and the scope of the present invention is not limited by the following examples and experimental examples. The following Examples and Experimental Examples can be appropriately modified and changed by those skilled in the art within the scope of the present invention.
실시예 1. 플로로탄닌을 함유한 조성물의 제조Example 1. Preparation of a composition containing fluorotannin
본 발명의 플로로탄닌을 유효성분으로 하는 장기능 개선용 조성물을 제조하기 위하여 국내산 갈조류로부터 하기의 방법으로 추출하였다.In order to prepare a composition for improving bowel function using fluorotannin of the present invention as an active ingredient, it was extracted from domestic brown algae by the following method.
감태(Ecklonia cava)를 증류수로 세척하여 이물질을 제거하고 음지에서 건조한 후, 이를 파쇄하였다. 추출용기에 상기 감태 500g을 담았으며, 상기 감태 중량 대비 20배의 30 중량% 주정 수용액을 첨가하고, 75 ~ 80℃에서 4시간 동안 환류 추출하여 추출액을 얻었다. 상기 추출액을 10㎛의 여과망에 여과하고, 여과된 추출물을 감압 농축하여 1차 추출농축액을 얻었다. 상기 1차 추출농축액을 진공건조기로 건조한 후, 분쇄하여 조성물 1을 170g 얻었다. Ecklonia cava was washed with distilled water to remove foreign substances, dried in the shade, and then crushed. 500g of the Ecklonia cava was put in an extraction container, and a 30% by weight aqueous alcohol solution of 20 times the weight of Ecklonia was added, followed by reflux extraction at 75 to 80°C for 4 hours to obtain an extract. The extract was filtered through a 10 μm filter network, and the filtered extract was concentrated under reduced pressure to obtain a first extract concentrate. The primary extract concentrate was dried with a vacuum dryer and then pulverized to obtain 170 g of Composition 1.
상기 조성물 1을 50℃의 온수에 용해한 뒤, 흡착수지에 흡착시킨 후, 물로 세척하고 주정으로 용출하여 플로로탄닌 용출액을 얻었다. 상기 용출액을 1㎛의 여과망에 여과하고, 여과된 추출물을 감압 농축하여 2차 추출농축액을 얻었다. 상기 2차 추출농축액을 진공건조기로 건조한 후, 분쇄하여 조성물 2을 30g 얻었다. The composition 1 was dissolved in hot water at 50° C., adsorbed on an adsorption resin, washed with water, and eluted with alcohol to obtain a fluorotannin eluate. The eluate was filtered through a 1 μm filter network, and the filtered extract was concentrated under reduced pressure to obtain a second extract concentrate. The secondary extract concentrate was dried with a vacuum dryer and then pulverized to obtain 30 g of composition 2.
이후 조성물 2를 20배량의 증류수에 현탁하고, 동일량의 에틸아세테이트 용매로 3회 추출하여 에틸아세테이트 분획을 얻었다. 상기 에틸아세테이트 분획을 감압 농축하고, 이 농축액을 진공건조기로 건조한 후, 분쇄하여 조성물 3을 10g 얻었다.Thereafter, the composition 2 was suspended in 20 times the amount of distilled water, and extracted three times with the same amount of ethyl acetate solvent to obtain an ethyl acetate fraction. The ethyl acetate fraction was concentrated under reduced pressure, and the concentrated solution was dried with a vacuum dryer and then pulverized to obtain 10 g of Composition 3.
조성물 3을 30% 메탄올에 용해시킨 후 역상 크로마토그래피를 이용 조성물 4 및 5를 분리하였다. 분리는 15 ~ 80% 메탄올 수용액을 이용하였고, 15 ~ 30% 농도의 메탄올 수용액으로 분리된 용액을 농축하여 조성물 4 2g을 얻었고, 30 ~ 80% 농도의 메탄올 수용액에서 분리된 용액을 농축하여 조성물 5 7g을 얻었다.After dissolving Composition 3 in 30% methanol, compositions 4 and 5 were separated using reverse phase chromatography. Separation was performed using a 15 to 80% methanol aqueous solution, and the separated solution was concentrated with a 15 to 30% aqueous methanol solution to obtain 2 g of Composition 4, and the solution separated from a 30 to 80% aqueous methanol solution was concentrated to obtain Composition 5 I got 7 g.
상기에서 제조한 조성물 1 ~ 5에 대하여 액체 크로마토그래피에 로딩(loading)하여 화합물 분리를 진행하였다. 이때 얻어진 화합물은 화학식 1 내지 12의 화합물임을 화합물 구조분석 장치 NMR을 이용하여 확인하였다. 상기에서 제조한 조성물에 대하여 60부피% 메탄올에 용해시킨 후 0.2㎛ 막여과지로 여과하여 고속 액체 크로마토그래피에 로딩(loading)하였다. 고속 액체 크로마토그래피에서, 컬럼은 HP ODS Hypersil, 용매는 증류수와 메탄올을 사용하였으며, 용매의 공급은 1.0㎖/분의 유속으로 메탄올 15부피%에서 70부피%까지 30분간에 걸쳐 선형구배(linear gradient)를 걸어 분석한 결과, 상기 화학식 1 내지 12의 화합물의 존재를 확인하였다. 상기 조성물의 화학적 조성을 하기 [표 1]에 나타내었다.Compound separation was carried out by loading the compositions 1 to 5 prepared above in liquid chromatography. At this time, it was confirmed that the obtained compound is a compound of Formulas 1 to 12 using a compound structure analysis device NMR. The composition prepared above was dissolved in 60% by volume of methanol, filtered through a 0.2 μm membrane filter, and loaded on high performance liquid chromatography. In high performance liquid chromatography, HP ODS Hypersil was used as the column and distilled water and methanol were used as the solvent, and the supply of the solvent was a linear gradient from 15% by volume to 70% by volume of methanol at a flow rate of 1.0 ml/min over 30 minutes. ) As a result of analysis, it was confirmed the presence of the compounds of Formulas 1 to 12. The chemical composition of the composition is shown in Table 1 below.
조성물 6으로 하기 조성의 플로로탄닌을 포함하는 조성물을 제조하였다.Composition 6 was used to prepare a composition containing fluorotannin of the following composition.
실시예 2. 조성물을 활용한 분말형 제품예의 제조Example 2. Preparation of a powdered product example using the composition
실시예 1의 조성물을 활용한 분말형 제품을 제조하기 위해 조성물 1~5에 덱스트린을 배합하여 제품예를 제조하였다. 제품예 1-5의 조성은 아래의 [표 2]와 같다. 제조된 제품예 3을 [도 2]에 나타내었다.In order to prepare a powdered product using the composition of Example 1, a product example was prepared by blending dextrin into the compositions 1 to 5. The composition of Product Example 1-5 is shown in [Table 2] below. The prepared Product Example 3 is shown in [Fig. 2].
1%Composition 3
One%
2%Composition 4
2%
3%Composition 5
3%
(단위: 중량%)(Unit: wt%)
상기 제품예는 그 자체로도 섭취가 가능하고, 일상생활 중 섭취하는 식품, 차류, 물, 음료 등에 첨가하여 사용할 수도 있다.The above product examples can be ingested by themselves, and can be added to food, tea, water, and beverages to be consumed during daily life.
실시예 3. 조성물을 활용한 액상형 제품예의 제조Example 3. Preparation of a liquid product example using the composition
실시예 1의 조성물을 활용한 액상형 제품을 제조하기 위해 조성물 1-5에 정제수를 배합하여 액상형 제품예 6-10를 제조하였다. 액상형 제품예 6-10의 조성은 아래의 [표 3]과 같다. 제조된 제품예 8을 [도 3]에 나타내었다.In order to prepare a liquid product using the composition of Example 1, purified water was added to the composition 1-5 to prepare a liquid product example 6-10. The composition of the liquid product example 6-10 is shown in [Table 3] below. The manufactured product example 8 is shown in [Fig. 3].
0.1%Composition 3
0.1%
0.15%Composition 4
0.15%
0.05%Composition 5
0.05%
염화나트륨 1%Citric acid 0.3%
1% sodium chloride
(단위: 중량%)(Unit: wt%)
상기 제품예는 그 자체로도 섭취가 가능하고, 일상생활 중 섭취하는 식품, 차류, 물, 음료 등에 첨가하여 사용할 수도 있다.The above product examples can be ingested by themselves, and can be added to food, tea, water, and beverages to be consumed during daily life.
실험예 1. 조성물의 효능 평가 실험Experimental Example 1. Efficacy evaluation experiment of composition
조성물 1-5에 대한 장기능 개선 효과를 다음과 같이 평가하였다. 평소 소화장애, 배변장애 등 장기능 이상 증상이 있는 성인 남녀 30명을 모집하고 무작위로 10명씩 세그룹을 조직한 후 각 그룹당 조성물 1 내지 5 중 한가지를 제공하고 한주간 섭취하게 한 후 장기능 개선에 대한 효과를 평가하였다. 장기능 개선에 대한 평가는 배변시간 및 양/질, 복부팽만감, 변의 색이나 냄새, 방귀가 생기는 정도 개선, 더부룩함 및 소화불량 개선의 항목에 대해 섭취 전, 후 2(나쁨), 4, 6, 8, 10(좋음)으로 평가하였다. 섭취 전, 후의 피험자별, 항목별 평균을 비교하여 조성물의 효능 평가를 하였다. 피험자는 조성물 사용 전 장기능 장애에 대한 평가를 하고 그룹별로 조성물 1 내지 5 중 한가지를 한 주동안 사용한 후 변화에 대한 평가를 하였다. 조성물의 적용은 평소 섭취하는 식품과 음료에 조성물을 1회 일인분 기준 0.01g을 첨가하여 하루에 세번 섭취하게 하였고, 조성물 외에 다른 장기능개선 작용을 하는 약품 및 건강기능식품의 복용을 중지하였다. 또한 섭취하는 식품, 음료의 주기도 조성물 적용전과 동일하게 유지하여 실험을 진행하였다. 평가의 결과를 [표 4]에 나타내었다. The effect of improving intestinal function for Composition 1-5 was evaluated as follows. Recruiting 30 adult men and women with symptoms of intestinal dysfunction such as digestive disorders and bowel disorders, and randomly organizing three groups of 10 people, providing one of compositions 1 to 5 for each group, and ingesting it for one week to improve bowel function. To evaluate the effect. For the evaluation of bowel function improvement, before and after ingestion 2 (bad), 4, 6 for items such as bowel time and quantity/quality, abdominal bloating, stool color or smell, degree of farting, and bloating and indigestion improvement. , 8 and 10 (good). The efficacy of the composition was evaluated by comparing the average of each subject and item before and after ingestion. Subjects evaluated for intestinal dysfunction before using the composition and evaluated for changes after using one of the compositions 1 to 5 for each group for one week. For application of the composition, 0.01 g of the composition was added per serving per serving to the usual food and beverage, and ingested three times a day, and drugs and health functional foods that improve bowel function other than the composition were stopped. In addition, the experiment was conducted by keeping the cycle of ingested food and beverage the same as before application of the composition. The results of the evaluation are shown in [Table 4].
하기 표 4에 의하면 본 발명의 조성물을 섭취하는 경우 배변시간 및 양/질, 복부팽만감, 변의 색이나 냄새, 방귀가 생기는 정도 개선, 더부룩함 및 소화불량 개선의 항목에서 섭취 전 대비 개선 효과가 뛰어난 것을 알 수 있다.According to Table 4 below, when ingesting the composition of the present invention, the improvement effect is excellent compared to before ingestion in the items of bowel time and quantity/quality, bloating sensation, stool color or smell, degree of fart occurrence, bloating and indigestion improvement. Can be seen.
실험예 2. 조성물을 활용한 제품의 효능 평가 실험Experimental Example 2. Efficacy evaluation experiment of a product using the composition
조성물을 활용한 제품예에 대한 장기능 개선 효과를 다음과 같이 평가하였다. 평소 배변장애 및 장기능 이상 증상이 있는 성인 남녀 30명을 모집하고 무작위로 15명씩 두그룹을 조직한 후 각 그룹당 제품예 2, 3, 6 및 8 중 한가지를 제공하고 한주간 섭취하게 한 후 장기능 개선에 대한 효과를 평가하였다. 피험자는 제품예 사용 전 장기능 장애에 대한 평가를 하고 그룹별로 제품예 2, 3, 6 및 8 중 한가지를 한주동안 사용한 후 변화에 대한 평가를 하였다. 장기능 개선에 대한 평가는 배변시간 및 양/질, 복부팽만감, 변의 색이나 냄새 개선, 방귀가 생기는 정도 개선, 더부룩함 및 소화불량 개선의 항목에 대해 섭취 전, 후를 2(나쁨), 4, 6, 8, 10(좋음)으로 평가하였다. 섭취 전, 후의 피험자별, 항목별 평균을 비교하여 조성물의 효능 평가를 하였다. 제품예의 적용은 평소 섭취하는 식품과 음료에 제품예 2, 3은 1회 일인분 기준 0.1g을 첨가하여 하루에 세번 섭취하게 하였고, 제품예 6, 8은 5방울을 식품과 음료에 첨가하여 섭취하게 하였다. 피험자는 조성물 외에 다른 장기능 개선 작용을 하는 약품 및 건강기능식품의 복용을 중지하였다. 또한 섭취하는 식품, 음료의 주기도 조성물 적용전과 동일하게 유지하여 실험을 진행하였다. 평가의 결과를 [표 5]에 나타내었다. The effect of improving bowel function for the product examples using the composition was evaluated as follows. Recruiting 30 adult men and women with normal bowel disorder and bowel dysfunction symptoms, randomly organized two groups of 15 people, and provided one of product examples 2, 3, 6, and 8 for each group, and allowed them to take it for one week. The effect on improvement was evaluated. Subjects evaluated for intestinal dysfunction before using the product examples, and evaluated changes after using one of product examples 2, 3, 6, and 8 for each group for one week. The evaluation of bowel function improvement was 2 (bad), 4 before and after ingestion for items such as bowel time and quantity/quality, abdominal bloating, stool color or odor improvement, fart occurrence, bloating and indigestion improvement. , 6, 8, 10 (good). The efficacy of the composition was evaluated by comparing the average of each subject and item before and after ingestion. The application of the product example was to add 0.1g per serving per serving to the foods and beverages to be consumed three times a day, and in product examples 6 and 8, 5 drops were added to food and beverages to ingest. I did. Subjects stopped taking drugs and health functional foods that improve intestinal function other than the composition. In addition, the experiment was conducted by keeping the cycle of ingested food and beverage the same as before application of the composition. The evaluation results are shown in [Table 5].
하기 표 5에 의하면 본 발명의 제품을 섭취하는 경우 배변시간 및 양/질, 복부팽만감, 변의 색이나 냄새, 방귀가 생기는 정도 개선, 더부룩함 및 소화불량 개선의 항목에서 섭취 전 대비 개선 효과가 뛰어난 것을 알 수 있다.According to Table 5 below, when ingesting the product of the present invention, the improvement effect is excellent compared to before intake in the items of bowel time and quantity/quality, bloating, stool color or smell, degree of farting, and bloating and indigestion improvement. Can be seen.
Claims (14)
[화학식 1]
[화학식 2]
[화학식 3]
[화학식 4]
[화학식 5]
[화학식 6]
[화학식 7]
[화학식 8]
[화학식 9]
[화학식 10]
[화학식 11]
[화학식 12]
[Formula 1]
[Formula 2]
[Formula 3]
[Formula 4]
[Formula 5]
[Formula 6]
[Formula 7]
[Formula 8]
[Formula 9]
[Formula 10]
[Formula 11]
[Formula 12]
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190080004 | 2019-07-03 | ||
| KR1020190080004 | 2019-07-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210005526A true KR20210005526A (en) | 2021-01-14 |
| KR102504458B1 KR102504458B1 (en) | 2023-02-28 |
Family
ID=74141204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200081536A KR102504458B1 (en) | 2019-07-03 | 2020-07-02 | Compositions and products containing phlorotannin for enhancing intestinal function |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102504458B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115998779A (en) * | 2023-01-16 | 2023-04-25 | 青岛科技大学 | Artemisia princeps polyphenol extract and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100486630B1 (en) | 2004-01-30 | 2005-05-03 | 오정해 | Functional dietary fiber supplement for the improvement of intestinal health and manufacturing method thereof |
| KR101979698B1 (en) | 2017-06-19 | 2019-05-17 | 주식회사 오즐디앤에프 | Composition for preventing, improving treating intestinal function depression comprising hydrolyzed and fermented bamboo sprout as an effective ingredient |
-
2020
- 2020-07-02 KR KR1020200081536A patent/KR102504458B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100486630B1 (en) | 2004-01-30 | 2005-05-03 | 오정해 | Functional dietary fiber supplement for the improvement of intestinal health and manufacturing method thereof |
| KR101979698B1 (en) | 2017-06-19 | 2019-05-17 | 주식회사 오즐디앤에프 | Composition for preventing, improving treating intestinal function depression comprising hydrolyzed and fermented bamboo sprout as an effective ingredient |
Non-Patent Citations (1)
| Title |
|---|
| Charoensiddhi, Suvimol, et al. "Polysaccharide and phlorotannin-enriched extracts of the brown seaweed Ecklonia radiata influence human gut microbiota and fermentation in vitro." Journal of Applied Phycology, Vol.29 (2017): 2407-2416.* * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115998779A (en) * | 2023-01-16 | 2023-04-25 | 青岛科技大学 | Artemisia princeps polyphenol extract and preparation method and application thereof |
| CN115998779B (en) * | 2023-01-16 | 2024-04-12 | 青岛科技大学 | Artemisia princeps polyphenol extract and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102504458B1 (en) | 2023-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101296693B (en) | Endurance improver | |
| JP2012097085A (en) | Lipase activity inhibitor containing polymer polyphenol fraction and tea extract, and process for production the same | |
| Xie et al. | Modulation of gut homeostasis by exopolysaccharides from Aspergillus cristatus (MK346334), a strain of fungus isolated from Fuzhuan brick tea, contributes to immunomodulatory activity in cyclophosphamide-treated mice | |
| CN107981324A (en) | Turmeric fermented food and preparation method thereof | |
| JP2006188486A (en) | Body fat accumulation-inhibiting or reducing agent | |
| Li et al. | Prebiotics and oxidative stress in constipated rats | |
| KR20050088994A (en) | Antioxidative composition | |
| CN107279978A (en) | A kind of special medicine purposes formula food suitable for tumour patient | |
| KR20160144791A (en) | Composition for relieving menopausal symptom | |
| Wang et al. | Heimao tea polysaccharides ameliorate obesity by enhancing gut microbiota-dependent adipocytes thermogenesis in mice fed with high fat diet | |
| JP2006193502A (en) | Adiponectin regulating agent and food, drink, food additive and medicine containing the same | |
| KR102504458B1 (en) | Compositions and products containing phlorotannin for enhancing intestinal function | |
| KR101028155B1 (en) | Beverage process for improving the immune action | |
| KR101859166B1 (en) | A composition for removing hangover comprising an herb extract including ginseng | |
| KR101088004B1 (en) | Composition for treating irritable bowel syndrome comprising fermented herbal mixture | |
| KR20170086198A (en) | Manufacturing method of diet solid tea including fermentation herb remedy and dietary fiber and the solid tea produced thereby | |
| CN113796537B (en) | Hypoglycemic composition and preparation process thereof | |
| KR20140016863A (en) | Anti-fatigue composition of plant material and preparation method, use and products thereof | |
| KR20190124061A (en) | Composition for treating or preventing metabolic disease | |
| KR20200043555A (en) | Supplement food composition for diet | |
| KR20210090557A (en) | Compositions containing phlorotannin for promoting height growth | |
| CN116268414A (en) | Composition for improving gastrointestinal function and preventing constipation and application thereof | |
| CN110859912A (en) | Traditional Chinese medicine composition for prostatitis and preparation method and application thereof | |
| KR20200143572A (en) | Composition for promoting digestion including oriental herbal extract | |
| KR20150119753A (en) | Composition for health foods of jelly type comprising aloe polysaccharide as an active ingredient and the method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |